Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization Primary endpoint win driven by both hard clinical outcomes and hospital resource utilization

PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism

NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y

Inari Medical, Inc. (NASDAQ:NARI ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Marissa Bych - VP, IR Drew Hykes - President and CEO Kevin Strange - CFO Tom Tu - Chief Medical Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG David Rescott - Baird Chris Pasquale - Nephron Research Stephanie Piazzola - Bank of America Lei Huang - Wells Fargo Zachary Day - Canaccord Genuity Michael Sarcone - Jefferies Ravi Misra - Truist Securities Matthew Blackman - Stifel Operator Good day, and welcome to the Inari Medical Third Quarter 2024 Earnings Call. [Operator Instructions] Also, please be aware that today's call is being recorded.

Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript

Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.05 per share a year ago.

Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates

IRVINE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today reported financial results for its third quarter ended September 30, 2024.

Inari Medical Reports Third Quarter 2024 Financial Results

ALISO VIEJO, Calif. , Oct. 21, 2024 /PRNewswire/ -- Okami Medical today announced the closing of a $32.5M financing led by new investor Vensana Capital and joined by existing investors including U.S. Venture Partners, members of Okami's board of directors, and other medical device industry veterans.

Okami Medical Announces Closing Of $32.5M Financing

Inari Medical (NARI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Inari Medical, Inc. (NARI) to Report a Decline in Earnings: What to Look Out for

IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will host an analyst and investor meeting to discuss the PEERLESS study following its presentation at the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The analyst and investor meeting will be held on Tuesday, October 29, 2024 at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time.

Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT Presentation

IRVINE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its third quarter 2024 financial results on Monday, October 28, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Third Quarter 2024 Financial Results

Shares of Inari Medical Inc (NARI, Financial) surged 3.22% in mid-day trading on Oct 2. The stock reached an intraday high of $42.21, before settling at $41.94, up from its previous close of $40.63.

Inari Medical Inc (NARI) Shares Up 3.22% on Oct 2

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) on behalf of the company's shareholders. Since January 2024, shares of Inari's common stock have declined in value from a trading price of over $65.00 per share to a current trading price of below $47.00 per share, a decline of over $18.00 per share, or approximately 28% in value. The investigation seeks to determine whether Inari and/or the company's officers and direc.

Kaskela Law LLC Announces Shareholder Investigation of Inari Medical, Inc. (NASDAQ: NARI) and Encourages Investors to Contact the Firm

NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) --  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that data from the PEERLESS trial will be presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine, during the Late-Breaking Clinical Trial Sessions at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. The presentation will take place on October 29th.

Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024

Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.

Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall

IRVINE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the following investor conferences:

Inari Medical to Present at Upcoming Investor Conferences

Abbott Labs

Edwards Lifesciences

Glaukos

iRhythm Technologies

Johnson & Johnson

SI-BONE Inc

While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.

7 Leading MedTech Stocks for Next-Gen Health Solutions

Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.

Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y

Start Time: 16:30 January 1, 0000 2:24 PM ET Inari Medical, Inc. (NASDAQ:NARI ) Q2 2024 Earnings Conference Call July 30, 2024, 16:30 PM ET Company Participants Drew Hykes - President and CEO Mitch Hill - CFO Tom Tu - Chief Medical Officer Kevin Strange - SVP of Finance, Accounting, Strategy and Business Development Marissa Bych - Gilmartin Group LLC Conference Call Participants Kallum Titchmarsh - Morgan Stanley Stephanie Pezzi - Bank of America Marie Thibault - BTIG Bill Plovanic - Canaccord Chris Pasquale - Nephron Research Adam Maeder - Piper Sandler Richard Newitter - Truist Margaret Kaczor - William Blair Operator Good afternoon, everyone, and welcome to the Inari Medical, Inc. Second Quarter 2024 Earnings Conference Call. All participants are in a listen-only mode.

Inari Medical, Inc. (NARI) Q2 2024 Earnings Call Transcript

Revenue increased by 22.5% year over year to $145.8 million. The healthcare company reported a significant net loss of $31.3 million, in contrast to its net profit of $2.1 million in the prior-year period.

Inari Medical's Renenue Rises, but Bottom Line Remains in the Red

Inari Medical, Inc. (NARI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.04 per share a year ago.

Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates

Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024 Mitch Hill to retire as Chief Financial Officer, to be succeeded by Kevin Strange in October 2024

Inari Medical Announces Chief Financial Officer Retirement and Succession Plan

Inari Medical (NARI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024 financial results on Tuesday, July 30, 2024. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce Second Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / July 12, 2024 / If you suffered a loss on your Inari Medical, Inc. (NASDAQ:NARI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inari-medical-inc-lawsuit-submission-form?prid=90574&wire=1 or contact Joseph E. Levi, Esq.

Inari Medical, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 12, 2024 to Discuss Your Rights - NARI

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

News for Inari Medical Stock (NARI)